Hologic Inc
$ 74.51
0.01%
29 Dec - close price
- Market Cap 16,618,384,000 USD
- Current Price $ 74.51
- High / Low $ 74.60 / 74.46
- Stock P/E 29.92
- Book Value 22.68
- EPS 2.49
- Next Earning Report 2026-02-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.11 %
- 52 Week High 75.34
- 52 Week Low 51.90
About
Hologic, Inc. (HOLX) is a premier medical technology innovator specializing in women's health, offering advanced diagnostic, surgical, and medical imaging solutions. The company’s extensive portfolio includes products and services focused on breast health and cervical cancer screening, positioning Hologic as a pivotal contributor to improving patient outcomes. With a significant emphasis on research and development, Hologic not only maintains its leadership in the healthcare sector but also drives meaningful innovations that enhance the quality of care worldwide.
Analyst Target Price
$76.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-03 | 2025-07-30 | 2025-05-01 | 2025-02-05 | 2024-11-04 | 2024-07-29 | 2024-05-02 | 2024-02-01 | 2023-11-09 | 2023-07-31 | 2023-05-01 | 2023-02-01 |
| Reported EPS | 1.13 | 1.08 | 1.03 | 1.03 | 1.01 | 1.06 | 1.03 | 0.98 | 0.89 | 0.93 | 1.06 | 1.07 |
| Estimated EPS | 1.1 | 1.05 | 1.02 | 1.02 | 1.01 | 1.02 | 0.98 | 0.95 | 0.84 | 0.89 | 0.88 | 0.91 |
| Surprise | 0.03 | 0.03 | 0.01 | 0.01 | 0 | 0.04 | 0.05 | 0.03 | 0.05 | 0.04 | 0.18 | 0.16 |
| Surprise Percentage | 2.7273% | 2.8571% | 0.9804% | 0.9804% | 0% | 3.9216% | 5.102% | 3.1579% | 5.9524% | 4.4944% | 20.4545% | 17.5824% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 1.09 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HOLX
2025-12-29 07:27:40
The Bone Sonometer Market is projected to grow from USD 1,336.8 Mn in 2025 to USD 1,996.8 Mn by 2032, exhibiting a CAGR of 5.9%. This growth is driven by rising industry demand, expanding applications, and technological advancements, according to a report by Coherent Market Insights. The report provides a comprehensive analysis of market drivers, restraints, opportunities, and competitive landscape, with a detailed regional assessment to inform strategic business decisions.
2025-12-29 06:08:25
The global skin rejuvenation devices market is projected to grow from US$2,227.4 million in 2022 to exhibit a CAGR of 9.5% during 2022-2030, driven by rapid innovation and shifting regional dynamics. This report offers strategic insights, segmentation by type, application, and region, and profiles key industry players like Cutera Inc. and Hologic Inc. It also highlights investment hotspots and production/consumption patterns to help stakeholders capitalize on upcoming opportunities.
2025-12-28 16:35:00
PSquared Asset Management initiated a significant $7.28 million stake in Core Scientific during the third quarter of 2025, betting on its stabilizing digital infrastructure and potential merger with CoreWeave. However, the stock price faced a 30% decline after the merger agreement was terminated due to shareholder disapproval. Despite this setback, Core Scientific still possesses valuable power infrastructure and is shifting its focus towards hosting and AI-adjacent workloads.
2025-12-28 10:35:00
PSquared Asset Management initiated a significant position in Core Scientific during the third quarter, which initially appeared to be a smart move due to the company's stabilizing digital infrastructure and potential merger. However, Core Scientific's stock price dropped by nearly 30% after the termination of its merger agreement with CoreWeave, raising questions about execution risk. Despite the stock plunge, the underlying operational shift towards hosting and compute services utilizing valuable power infrastructure remains.
2025-12-25 03:07:49
This article reviews the Q3 earnings for medical devices & supplies - imaging, diagnostics stocks, highlighting Hologic (NASDAQ:HOLX), QuidelOrtho (QDEL), GE HealthCare (GEHC), and Lantheus (LNTH). The industry faces challenges like high development costs and regulatory hurdles but benefits from consistent demand and technological advancements. Hologic showed strong revenue growth, QuidelOrtho outperformed expectations with a guidance raise, GE HealthCare had good results despite being the "weakest," and Lantheus beat analyst estimates significantly.
2025-12-24 21:38:10
Hologic stock (HOLX) experienced after-hours trading around $74.80 on Christmas Eve 2025, influenced by its pending acquisition by Blackstone and TPG for up to $79 per share, including a non-tradable Contingent Value Right (CVR). A key concern for investors is the reported difficulty in achieving the 2026 CVR milestone after Hologic stopped shipping specific breast biopsy needles. The CVR's value is directly tied to Breast Health revenue, making any product disruption a crucial factor for the market as it assesses the deal's overall value and closing conditions.
